Recent Updates
Recently added Catalysts

Seaport Therapeutics, Inc.

SPTXFDA catalysts, PDUFA dates & pipeline intelligence
$18.17
▼ -0.95 · -4.97%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SPTX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $14.8552W HIGH $19.17
Volume
278.25 K
Value Traded
5.08 M
Short % Float
27.05%
Days to Cover
17.4
-14.73%Week
+2.14%1 Month
-25.59%3 Month
+15.15%6 Month
-8.71%5 Year
-8.71%All Time

Cash Data

Unlock SPTX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
972.65 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
682.22 M
Total Shares
53.53 M
Float Shares
13.80 M
Insiders
74.22%
Institutions
33.75%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2b topline data readout
GlyphAlloTM (SPT-300, Glyph Allopregnanolone)
Major Depressive Disorder (MDD)
Phase 2bSmall MoleculesPsychiatry
Unlock every SPTX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SPTX Catalyst Timeline

Dated clinical, regulatory and corporate events for Seaport Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Seaport Therapeutics, Inc.

45Total events
13Upcoming
14Tier-1 (high impact)
2026 to 2029Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
GlyphAllo
T2Trial Initiation
Subscribe to view catalyst details
GlyphAgo

Event history 24

●Quarterly UpdateCorporate
Seaport reports third quarter 2026 financial results
●Poster PresentationGlyphAgoPresentation
Poster presentation of Phase 1 PK data for GlyphAgo at 39th ECNP Congress
▲PK PD DataGlyphAgoClinical Data
Detailed Phase 1 PK data for GlyphAgo presented at ECNP, including MAD portion and food effect analyses
▲PK PD DataGlyphAgoClinical Data
Detailed Phase 1 PK data for GlyphAgo: dose-dependent exposure, no food effect, no accumulation
generalized anxiety disordersource ↗
▲First Patient DosedGlyphAgoTrial
First patient dosed in Phase 2a trial of GlyphAgo in GAD and sleep disturbance
Generalized Anxiety Disorder and Sleep Disturbancesource ↗
▲PK PD DataGlyphAgoClinical Data
Additional pharmacokinetic data from Phase 1 GlyphAgo trial presented at ECNP Congress
generalized anxiety disorder (GAD)source ↗
▲First Patient DosedGlyphAgoTrial
First patient dosed in Phase 2a trial of GlyphAgo in GAD and sleep disturbance
generalized anxiety disorder (GAD) and sleep disturbancesource ↗
▲Topline ReadoutGlyphAlloClinical Data
Positive topline results from Phase 1 Driving Simulation Trial of GlyphAllo in healthy volunteers
healthy volunteers (driving impairment)source ↗
▲Primary Endpoint MetGlyphAlloClinical Data
Primary endpoint met: evening dosing of GlyphAllo 375 mg did not impair next-morning driving vs placebo on Day 5
healthy volunteers (driving impairment)source ↗
▲Secondary Endpoint DataGlyphAlloClinical Data
Key secondary endpoint met: single evening dose of GlyphAllo 250 mg did not impair next-morning driving vs placebo on Day 2
healthy volunteers (driving impairment)source ↗
Unlock the full SPTX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SPTX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-11GlyphAgo (SPT-320, Glyph Agomelatine) Phase 1 data presentation Phase 1
Unlock 1 more SPTX historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 52%
Micro Cap
(rank 377 of 725)
Percentile Rank
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
SPT-300 Small MoleculesNCT07161700Major Depressive Disorder (MDD)Phase 2 ENROLLING BY_INVITATION 720May 1, 2027
Unlock the SPTX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SPTX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
GlyphAllo driving performancePhase 12026-11-02GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5; a single evening dose of 250 mg GlyphAllo did not impair next-morning driving performance compared to placebo on Day 2Read MoreSeaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressRead More
Scroll for more · summaries link to the source press release
Unlock every SPTX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SPTX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Torres DeniceDirectorBuy 5,000 5,000 held$19.87 11/03/2026
Unlock the full SPTX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Sofinnova Investments, Inc. 3.1 % (-22.5 %) 71.90 M 3.56 M
Unlock every fund holding SPTX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SPTX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SPTX ownership
Insider and institutional ownership, quarter by quarter.

SPTX Short Interest

Shares sold short, counted twice a month.

27.05%
Short % of Float
of tradable shares sold short
3.7M
Shares Sold Short
+0.4% vs prior count
17.4 Very high
Days to Cover
trading days of normal volume to buy every short share back
214.3K
Avg Daily Volume
the average used for days to cover
Unlock SPTX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock SPTX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SPTX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SPTX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SPTX ranks across every disease it competes in

Competitive Position is a premium feature
See how SPTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SPTX News

SPTX
Nov 2, 2026
SPTXPhases

Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics reported positive topline data from its Phase 1 trial of GlyphAllo, indicating no impairment in driving performance. The company has initiated a Phase 2a trial for GlyphAgo in generalized anxiety disorder and is on track with enrollment for its Phase 2b BUOY-1 trial for major depressive disorder. Seaport's financial position remains strong, with $403.8 million in cash.

Read more →
SPTX
Oct 28, 2026
SPTXConferences/Events

Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference

Seaport Therapeutics will present at the Stifel 2026 Healthcare Conference from November 10-12, 2026. The management team is scheduled to speak on November 10 at 4:00 p.m. EST. The company will also hold one-on-one meetings with investors during the event. A live webcast will be available on their website.

Read more →
SPTX
Oct 9, 2026
SPTXPhases

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Seaport Therapeutics has presented additional pharmacokinetic data from its Phase 1 clinical trial of GlyphAgo™ at the 39th ECNP Congress in Munich. This marks the first scientific presentation of data related to GlyphAgo™, a novel neuropsychiatric medicine. The event highlights Seaport's commitment to advancing its therapeutic pipeline.

Read more →
SPTX
Oct 7, 2026
SPTXPhases

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Seaport Therapeutics, a company founded by PureTech, has announced the dosing of the first patient in its Phase 2a clinical trial for GlyphAgo™. This trial aims to evaluate the efficacy of GlyphAgo™ in patients suffering from generalized anxiety disorder and sleep disturbances. The development marks a significant step forward in addressing these mental health challenges.

Read more →
SPTX
Oct 7, 2026
SPTXPhases

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Seaport Therapeutics has announced that the first patient has been dosed in its Phase 2a clinical trial for GlyphAgo. This trial aims to evaluate the efficacy of GlyphAgo in treating patients with generalized anxiety disorder and sleep disturbances. The development represents a significant step forward in addressing these mental health conditions.

Read more →
SPTX
Sep 14, 2026
SPTXConferences/Events
▲ +5.8%on this news

Seaport Therapeutics to Participate in September Investor Conferences

Seaport Therapeutics, a clinical-stage company focused on neuropsychiatric medicines, announced its participation in several investor conferences in September. The events will include a presentation and panel discussion led by CEO Daphne Zohar at the Goldman Sachs Life Sciences Symposium. This engagement aims to enhance investor relations and showcase the company's developments.

Read more →
SPTX
Sep 9, 2026
SPTXPhases
▼ -9.6%on this newsshared move

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Seaport Therapeutics has announced positive topline results from its Phase 1 driving simulation trial of GlyphAllo™. The trial, conducted with healthy volunteers, indicates the potential safety and efficacy of the product. This development marks a significant step forward for Seaport Therapeutics in their research efforts.

Read more →
SPTX
Aug 31, 2026
SPTXConferences/Events

Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

Seaport Therapeutics has announced its participation in two significant events: Citi's 2026 Biopharma Back to School Conference and the 21st Annual Wells Fargo Healthcare Conference. These presentations are expected to provide insights into the company's developments and foster investor relations. The participation reflects the company's commitment to engaging with the biopharma community.

Read more →
SPTX
Aug 3, 2026
SPTXGeneral

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics has announced its financial results for the second quarter of 2026, showcasing notable corporate and clinical advancements. The report emphasizes the company's ongoing progress in its initiatives, reflecting a positive outlook for future developments.

Read more →
SPTX
Jun 9, 2026
SPTXPhases
▲ +9%on this news

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics, a company founded by PureTech, has announced positive results from its Phase 1 proof-of-concept trial of GlyphAgo™. The trial involved healthy volunteers and demonstrated encouraging data regarding the drug's safety and efficacy. These findings suggest potential for further development in the therapeutic landscape.

Read more →
SPTX
Jun 8, 2026
SPTXGeneral

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics reported its Q1 2026 financial results, highlighting advancements in its clinical programs for neuropsychiatric disorders. The company is actively enrolling patients in the Phase 2b BUOY-1 trial for GlyphAllo, with topline data expected in early 2027. Additionally, new data from the GlyphAgo program indicate promising safety and efficacy profiles. The recent IPO raised $260 million to support ongoing development.

Read more →
SPTX
Jun 8, 2026
SPTXPhases

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics has announced positive results from a Phase 1 proof-of-concept trial for GlyphAgo™, demonstrating its safety and tolerability in healthy volunteers. The multiple-ascending dose data supports further development of the therapy. This marks a significant milestone for the company in advancing GlyphAgo™.

Read more →
SPTX
Jun 1, 2026
SPTXConferences/Events
▼ -5.8%on this news

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Seaport Therapeutics, a clinical-stage company, announced its participation in two upcoming investor conferences: the Goldman Sachs 47th Annual Global Healthcare Conference and the UBS Virtual CNS Day. Management will engage in fireside chats and one-on-one meetings, showcasing their commitment to investor relations. The company focuses on developing novel treatments for neuropsychiatric disorders.

Read more →
SPTX
May 1, 2026
SPTXGeneral

Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

Seaport Therapeutics has announced the pricing of its upsized initial public offering, offering 14,160,000 shares at $18.00 each, totaling approximately $254.9 million. The shares are set to begin trading on the Nasdaq Global Select Market on May 1, 2026. The offering is expected to close on May 4, 2026, pending customary conditions.

Read more →
SPTX
Apr 27, 2026
SPTXGeneral

Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

Seaport Therapeutics has appointed Dr. Sharon Mates, the founder and former CEO of Intra-Cellular Therapies, to its Board of Directors. Dr. Mates has a strong background in neuropsychiatry and played a key role in the commercialization of the antipsychotic CAPLYTA. Her expertise is expected to enhance Seaport's mission to develop innovative treatments for neuropsychiatric disorders.

Read more →
SPTX
Apr 2, 2026
SPTXPhases

Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics announced positive topline results from its Phase 1 trial of GlyphAgo, a novel prodrug of agomelatine. The trial demonstrated a significant increase in bioavailability and reduced pharmacokinetic variability. GlyphAgo was well-tolerated, with no serious adverse effects reported, paving the way for further clinical trials in generalized anxiety disorder.

Read more →
SPTX
Mar 25, 2026
SPTXPhases

Seaport Therapeutics Announces Science Translational Medicine Peer-Reviewed Publication Featuring GlyphAllo (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

Seaport Therapeutics announced the publication of findings on GlyphAllo, a novel oral prodrug of allopregnanolone, in Science Translational Medicine. The study confirms its therapeutic potential in major depressive disorder (MDD) and supports the ongoing Phase 2b trial. GlyphAllo's unique formulation allows for enhanced bioavailability, making it a promising candidate for treating MDD.

Read more →
SPTX
Mar 3, 2026
SPTXGeneral

Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function

Seaport Therapeutics has received up to $15 million from ARPA-H to advance GlyphCele, an oral prodrug targeting gut lymphatic dysfunction. This innovative therapy aims to address issues linked to metabolic diseases and pancreatic cancer by restoring lymphatic function. The collaboration with Monash Institute of Pharmaceutical Sciences enhances the potential impact of this research.

Read more →
SPTX
Feb 20, 2026
SPTXConferences/Events

Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials

Seaport Therapeutics presented a meta-analysis at the ISCTM Conference, revealing that clinician-administered assessments significantly influence placebo responses in generalized anxiety disorder trials. The study examined 22 trials and found no strong correlation with other design factors. This research builds on previous findings in major depressive disorder, emphasizing the need for optimized clinical trial designs to enhance drug development success.

Read more →
SPTX
Feb 18, 2026
SPTXConferences/Events

Seaport Therapeutics to Participate in Upcoming Investor Conferences in February and March

Seaport Therapeutics has announced its participation in several upcoming investor conferences in February and March 2026. The conferences include the Oppenheimer 36th Annual Healthcare Life Sciences Conference, the Leerink Partners Global Healthcare Conference, and the Stifel 2026 Virtual CNS Forum. The company aims to showcase its advancements in neuropsychiatric medicines and highlight its proprietary Glyph technology platform.

Read more →

About Seaport Therapeutics, Inc.

Boston, MA seaporttx.com
Headquarters6 TIDE STREET, BOSTON, MA, 02110
BIOPHARMAWATCH ELITE
Trade the next SPTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime